56 CHEMOTHERAPY JAN Fig. 1 Effect of Mezlocillin on respiration, blood pressure and ECG in the rabbit

Similar documents
Fig. 1 Effect of T-1220 on blood pressure and respiration of the rabbit Fig. 2 Effects of T-1220 and P-32 on blood pressure of the rabbit

VOL. 28 S-2 CHEMOTHERAPY

Table 1 SEDATIVE-ATAXIC SCORE Verical wooden pole cm high and cm thick Inclined screen (wire-mesh screen) tilted at an angle of 45 to the

CHEMOTHERAPY Table 1 Urinary excretion of mezlocillin Fig. 4 Urinary excretion of mezlocillin Fig. 3 Blood levels of mezlocillin

1272 CHEMOTHERAPY MAR. 1975

VOL. 23 NO. 3 CHEMOTHERAPY 1067 Table 2 Sensitivity of gram positive cocci isolated from various diagnostic materials Table 3 Sensitivity of gram nega

VOL.32 S-7 CHEMOTHERAPY Table 1 MIC of standard strains of CTRX Fig. 2 Cumulative curves of MIC S. aureus (26 strains )

988 CHEMOTHERAPY NOV. 1971

Fig. 1 Chemical structure of DL-8280

CHEMOTHERAPY FEB Table 1 Background of volunteers

CHEMOTHERAPY FEB Table 1. Activity of cefpirome and others against clinical isolates


VOL.27S-1 CHEMOTHERAPY 109 Klebsiella, Proteus, Pseudomonas Streptococcus Fig. 1 Concentration in blood and in CSF after intravenous drip infusion of


CHEMOTHERAPY APR Fig. 1 Chemical structure of cefotetan (CTT, YM09330)

VOL.39 S-3


CHEMOTHERAPY NOV S. aureus, S. epidermidis, E. coli, K. pgeumoniae, E. cloacae, S. marcescens, P. mirabilis, Proteus, P. aeruginosa Inoculum siz


CHEMOTHERAPY JUN Citrobacter freundii 27, Enterobacter aerogenes 26, Enterobacter cloacae 27, Proteus rettgeri 7, Proteus inconstans 20, Proteus

VOL.27 CHEMOT S-1 HERAPY 185 に感 性 を示 して い たが,臨 床 的 に は無 効 で あ った 本 症 る 細 菌学 的 に も検 討 した が,起 炎菌 と考 え られ る細 菌 を 例 で は 基礎 疾 患 と して縦 隔 洞腫 瘍 が あ り,既 に 副 腎

CHEMOTHERAPY SEPT. 1970



VOL. 23 NO. 3 CHEMOTHERAPY 1379 Table 1 Susceptibility of clinical isolated strains to Tobramycin


Clostridium difficile ciprofloxacin, ofloxacin, norfloxacin Bifidobacterium Lactobacillus Lactobacillus Bacteroides fragilis B. fragilis C. difficile

epidermidis, Enterococcus faecalis, Enterococcus Klebsiella pneumoniae, Proteus mirabilis, indolepositive Proteus spp., Enterobacter spp., Serratia

VOL. 34 S-2 CHEMOTH8RAPY 913


CHEMOTHERAPY

CHEMOTHERAPY Fig. 1 Body weight changes of pregnant mice treated orally with AM- 715 Day of sestation

CHEMOTHERAPY JUNE 1986

Fig.1 Chemical structure of BAY o 9867



VOL.32 S-3 CHEMOTHERAPY


CHEMOTHERAPY Fig. 1 Chemical structure of CXM-AX

Table 1. Antibacterial activitiy of grepafloxacin and other antibiotics against clinical isolates

CHEMOTHERAPY aureus 0.10, Enterococcus faecalis 3.13, Escherichia coli 0.20, Klebsiella pneumoniae, Enterobacter spp., Serratia marcescens 0.78, Prote

CHEMOTHERAPY

Table1MIC of BAY o 9867 against standard strains

2108 CHEMOTHERAPY SEPT Table 1 Antimicrobial spectrum Fig. 1

VOL.35 S-2 CHEMOTHERAPY Table 1 Sex and age distribution Table 2 Applications of treatment with carumonam Table 3 Concentration of carumonam in human

Fig. 1 Chemical structure of KW-1070

CHEMOTHERAPY SEPT. 1991


CHEMOTHERAPY

Table 1. Antibacterial spectrum SBT ABPC ABPC CPZ : sulbactamiampicillin : ampicillin : cefoperazone


CHEMOTHERAPY APR. 1982

VOL.42 S-1


CHEMOTHERAPY APR Fig. 2 The inactivation of aminoglycoside antibiotics by PC-904 Fig. 3 Serum concentration of PC-904 (1) Fig. 4 Urinary recover

Fig. 1 Chemical structure of TE-031 Code number: TE-031 Chemical name: (-) (3R, 4S, 5S, 6R, 7R, 9R, 11R, 12R, 13S, 14R)-4-[(2, 6-dideoxy-3-C-methyl-3-

VOL. 20 NO. 5 CHEMOTHERAPY Methoxy-4-sulfanilamidopyrimidine (OS-3376) Sulfadimethoxine (SDM) Table 1. In vitro antibacterial activities of OS-3

coccus aureus Corynebacterium sp, Haemophilus parainfluenzae Klebsiella pneumoniae Pseudornonas aeruginosa Pseudomonas sp., Xanthomonas maltophilia, F

CHEMOTHERAPY JUNE 1993 Table 1. Background of patients in pharmacokinetic study

VOL. 40 S- 1 Table 1. Susceptibility of methicillin-resistant Staphylococcus aureus to meropenem Table 2. Coagulase typing of methicillin-resistant St

CHEMOTHERAPY NOV. 1990

CHEMOTHERAPY Proteus mirabilis GN-79 Escherichia coli No. 35 Proteus vulgaris GN-76 Pseudomonas aeruginosa No. 11 Escherichia coli ML-1410 RGN-823 Kle

Fig. 1 Chemical structure of norfioxacin (AM-715)

A Nutritional Study of Anemia in Pregnancy Hematologic Characteristics in Pregnancy (Part 1) Keizo Shiraki, Fumiko Hisaoka Department of Nutrition, Sc

CHEMOTHERAPY OCT Fig. 1 Chemical structure of CVA-K


VOL.30 S-1 CHEMOTHERAPY Table 1 Antibacterial activity of CTT against standard strains Table 2 Antibacterial activity of CTT against standard strains

日本化学療法学会雑誌第51巻第2号

Staphylococcus sp. K.pneumoniae P.mirabilis C.freundii E. cloacae Serratia sp. P. aeruginosa ml, Enterococcus avium >100ƒÊg/ml


Key words:fatty acid,plant oil,staphylococcus aureus,skin care, atopic dermatitis


Key words : 7432-S, Oral cephem, Urinary tract infection Fig. 1. Chemical structure of 7432-S.

Table 1. Influence of food deprivation on gastric secretion and severity of ulceration in 18 hr pylorus ligated rats.

CHEMOTHERAPY JUNE 1987 Table1 Media used *BHIB, brain heart infusion broth (Difco); /3 -NAD, S -nicotinamidoadeninedinucleotide (Sigma Chemical Co.);

Experimental and Clinical Studies of Pregnant Hypertension Takashi SHIMAZU Department of Obstetrics and Gynecology, Osaka City University Medical Scho

Jan THE JAPANESE JOURNAL OF ANTIBIOTICS XL-1 Table 1. Outline of administering doses, routes and sampling times *: 4 ml/hr/kg Bacillus subtilis




CHEMOTHERAPY

CHEMOTHERAPY MAY. 1988


untitled

CHEMOTHERAPY

VOL.47 NO.5 Table 1. Susceptibility distribution of Ĉ- lactams against clinical isolates of MRSA MRSA: rnethicillin- resistant Staphylococcus aureus

106(18) 原 使 用 した 測 定 部 位 は 期 門 穴相 当部 位 の 表 皮 上 及 び 真 皮 下 と し, 表 皮上 で は 艾 柱 の 直 下 に 熱 電 対 先 端 を露 出 し固 定 した 真 皮 下 で は施 灸部 より10mm 下 方 を切 開 剥 離 し, 施 灸 部 直

CHEMOTHERAPY Table 1 Clinical effect of Sultamicillin

THE JAPANESE JOURNAL OF ANTIBIOTICS 65 6 Dec LVFX 100 mg 3 / mg 2 / LVFX PK PD mg mg 1 1 AUC/MIC

CHEMOTHERAPY DEC Table 1 Antibacterial spectra of T-1982, CTT, CMZ, CTX, CPZ and CEZ 106 CFU/ml Note: P; Peptococcus, S; Streptococcus, G; Gaffk

Key words: E. coli O 157: H7, fosfomycin, verotoxin, mouse infection


Table 1. Concentration of ritipenem in plasma, gallbladder tissue and bile after ritipenem acoxil administration (200 mg t.i.d., 3 days) N.D.: not det

Dec. THE JAPANESE JOURNAL OF ANTIBIOTICS XXXVII (45)


Title 泌尿器科領域に於ける17-Ketosteroidの研究 17-Ketosteroidの臨床的研究 第 III 篇 : 尿 Author(s) 卜部, 敏入 Citation 泌尿器科紀要 (1958), 4(1): 3-31 Issue Date URL

Key words: Disinfectants, Gram negative rods, Bactericidal effect P. aeruginosa 1, P. fluorescens 20 P. putida 179, P. cepacia 216 P. maltophilia 227,

日本消化器外科学会雑誌第25巻第11号

CHEMOTHERAPY JUNE 1988 ( })-1-ethyl-6,8-difluoro-1,4-dihydro-7-(3-methyl-l-piperaziny1) 4-oxo-3-quinolinecarboxylic acid hydrochloride Fig. 1. Chemica


Transcription:

VOL.27 S-1 CHEMOTHERAPY 55

56 CHEMOTHERAPY JAN. 1979 Fig. 1 Effect of Mezlocillin on respiration, blood pressure and ECG in the rabbit

VOL.27 CHEMOT S-1 Fig. 2 Effect of Mezlocillin on blood pressure (Sensitivity Fig. 3 1 Effect よ びAd感 処 受 性 に ま っ た く影 響 を 与 ウサ ギ心 電 図に 対 す る作 用 Mezlocillinの50 400mg/kg適 心 電 図(第II誘 QRS間 った 3. rate of the rabbit 摘 出 モ ル モ ッ ト心 房 に 対 す る 作 用 Mezlocillinの10-7 5 10-3g/ml 導)は は,Fig.4に 用 時 の無 麻 酔 ウサ ギ 各 棘 波 お よ び 波 形,PQ間 隔 に ほ と ん ど 変 化 は み ら れ ず,心 も,Table1に on heart of the rabbit Tyrode液 の 摘 出 モ ル モ ッ ト心 房 の 自動 運 動(振 え なか った 2. of the rabbit to acetylcholine) of Mezlocillin 昇 し た が,Mezlocillinの50mg/kg前 置 に よ り,Achお and respiration Effect of Mezlocillin on blood pressure and respiration (Sensitivity to adrenaline) Table 42mmHg上 57 HERAPY し め す よ うに,ほ 隔, 拍 数 に 対 して と ん ど影 響 を 与 え な か し め す よ う に,ほ 適用時 幅 お よ び 拍 動 数) とん ど変 化 は み られ な か っ た 4. a. 血 管 に対 す る作 用 摘 出 ウサ ギ耳 殻 血 管 灌 流 量 Mezlocillinの10-5 2 10-1g/ml の,摘 出 ウ サ ギ 耳 殻 血 管 灌 流 量(1分 Locke液 間)は,Fig.5に 適用時

Fig. 4 Effect of Mezlocillin on the isolated atrium of the guinea pig Fig. 5 Effect of Mezlocillin on the rabbit ear vessels Fig. 6 Effect of Mezlocillin on permeability of the rabbit skin vessels

VOL.27 CHEMOT S-1 しめ す よ うに,適 /ml適 用 前61滴/分 用 例 で は61 65滴/分 い が,5 10-2g/ml適 に 対 し,10-5 2 10-2g で あ り,ほ で あ り,6 10分 透 過 性 を,対 Fig.7に 後 に 回復 した b. Locke液 適用時の色素 ら に,Hist 用 例 で は,Locke液 で あ る が,1,000μg適 摘 出 モ ル モ ッ ト腸 管 しめ す う に,ほ と同一 程 度 2. 用 例 では 僅 か に 充 進す る傾 向を し Fig. 8 Fig. 9 Effect Effect of Mezlocillin of Mezlocillin of Mezlocillin 適用時 とん ど 変 化 は み られ な か っ た Mezlocillinの10-7 10-3g/ml on the on the on the isolated isolated isolated しめ す よ 摘 出 モ ル モ ッ ト気 管 筋 に 及 ぼ す 影 響 用 時 の,摘 Effect Tyrode液 の 摘 出 モ ル モ ッ ト腸 管 の 筋 緊 張 は,Fig.8に め した Fig. 7 幅 お よ び 筋 緊 張)は, と ん ど変 化 は み ら れ な か っ Mezlocillinの10-7 5 10-39/ml 10μg そ れ と比 較 し た Fig.6に よ う に0.1 100μg適 し め す よ う に,ほ 適用時 た 照 と し てLocke液,さ お よ びAch1μgの Tyrode液 の 摘 出 ウ サ ギ 腸 管 の 自 動 運 動(振 でpeak ウサ ギ皮 膚 血 管透 過 性 Mezlocillinの0.1 1,000μg 摘 出腸 管 に対 す る作 用 摘 出 ウサ ギ腸 管 Mezlocillinの10-7 2 10-39/ml と 管拡 張 作 用 のあ る こ と を み と め た そ の 際 の 経 時 的 変 化 は2分 平 滑筋 に及 ぼ す 影 響 1. a. 用 例 で は81滴/分 適 用 量 に ほ ぼ 比 例 し て 滴 数 が 増 加 し,血 b. II とん ど変 化 は な 用 例 で は70滴/分,10-lg/ml適 用 例 で は75滴/分,2 10-1g/ml適 59 HERAPY 出 モ ル モ ッ ト気 管 筋 緊 張 は,Fig.9に intestine intestine trachea Ringer-Locke液 of the of the of the rabbit guinea guinea pig pig 適 しめ

Fig.10 Effect of Mezlocillin on the isolated non pregnant uterus of the rat Fig.11 Effect of Mezlocillin on the isolated pregnant uterus of the rat Table 2 Effect of Mezlocillin on paralytic action in mice * Score 3 according to the method of KAUZMANOFF

Table 3 Effect of Mezlocillin on cornea reflex in the rabbit Table 4 Urinary excretion of electrolytes and urinary findings in the rat applied Mezlocillin subcutaneously once a day for 7 days Urinary findings: ph 6.1 `7.2 glucose 0 protein 25 `50 mg/100 ml urobilinogen 0.1 u/100 ml ketone body 0 `5 mg/100 mloccult blood 0 * Maximum levels are indicated the maximum decrease or increase during the drug administration well as that applied time in parenthesis., as

Table 5 General pharmacological properties of Mezlocillin and Carbenicillin 1) BODEY G. P. & T. PAN: Mezlocillin; In vitro studies of a new broad spectrum penicillin. Antimicrob. Agents Chemother. 11 : 74-79, 1977 2) KRASEMANN C.: In vitro activity of Mezlocillin and Azlocillin against gramnegative rods and grampositive cocci: 16th Interscience Conference on Antimicr. Agents & Chemoth. 346, 1976 3) WERNER H. & C. KRASEMANN : Susceptibility of Bacteroidaceae to Mezlocillin, Azlocillin and carbenicillin: 16 th Interscience Conference on Antimicr. Agents & Chemoth. 347, 1976 4) LODE H.; U. NIESTRATH, P. KOEPPE & H LANGMAACK: Clinical pharmacology of two new semi-synthetic penicillins: Mezlocillin and Azlocillin: 16 th Interscience Conference on Antimicr. Agents & Chemoth. 348, 1976

CHEMOTHERAPY 63 PHARMACOLOGICAL STUDIES ON MEZLOCILLIN, FIRST REPORT: GENERAL PHARMACOLOGY YASUMITSU YAMANAKA, SHIZUKO KONO, HIDEKI TATEISHI and HARUE ARATANI Department of Pharmacology, Hiroshima University, School of Medicine, Hiroshima, Japan The pharmacological actions of Mezlocillin, a new type of semisynthetic penicillin effective against severe infections by gram-negative bacilli, were investigated. Pharmacological actions and minimal effective doses (MED) were as follows: dilation of isolated rabbit ear vessels (5 ~10-2 g/ml), slight stimulation of permeability of rabbit abdominal skin vessels (1,000 Đg), inhibition of isolated guinea pig trachea (10-3 g/ml) and inhibition of isolated rat non-pregnant and pregnant uteri (10-3 and 2 ~10-3 g/ml). No effect was observed on rabbit blood pressure and respiration (100 mg/kg), on rabbit ECG (400 mg/kg), on isolated guinea pig atrium (5 ~10-3 g/ml), or isolated rabbit and guinea pig intestine (2 ~10-3 and 5 ~ 10-3 g/ml). Muscular paralysis and local anesthetic action were not observed in doses of 10 g/kg and 2 ~10-1 g/ml, respectively. MED of Mezlocillin were much larger than minimal inhibitory concentrations and maximal blood levels in clinical uses, and were similar to those of Carbenicillin. The increase in body weight, volume of urine, urinary excretion of sodium and potassium, and urinary findings in the rat applied Mezlocillin in doses from 25 to 100 mg/kg subcutaneously once a day for 7 days were similar to normal values and those of the control group.